Twice‐daily compared with once‐daily insulin glargine in people with Type 1 diabetes using meal‐time insulin aspart
Authors:
- 25 May 2006
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 23 (8) , 879-886
Abstract
Aims To compare blood glucose control when using insulin glargine twice daily at breakfast‐ and dinner‐times with insulin glargine once daily at dinner time, in unselected people with Type 1 diabetes using insulin aspart at meal‐times.Methods In this 8‐week, two‐way, cross‐over study, 20 people with Type 1 diabetes were randomized to insulin glargine injection once daily at dinner‐time or twice daily at breakfast‐ and dinner‐times, both plus meal‐time insulin aspart. Each 4‐week treatment period concluded with a 24‐h inpatient metabolic profile.Results Insulin doses, HbA1c, fructosamine concentration and pre‐breakfast self‐monitored blood glucose (SMBG) concentration did not differ between treatment periods. SMBG concentrations after breakfast, after lunch and before dinner were lower with twice‐daily compared with once‐daily dinner‐time glargine [9.3 ± 0.5 (± se) vs. 6.7 ± 0.5 mmol/l, P = 0.003; 10.2 ± 0.9 vs. 7.0 ± 0.9 mmol/l, P = 0.024; 9.6 ± 0.5 vs. 6.6 ± 0.5 mmol/l, P = 0.001]. Mean 24‐h SMBG concentration was lower with twice‐daily glargine (7.1 ± 0.5 vs. 8.8 ± 0.5 mmol/l, P = 0.031). Within‐day variability of SMBG concentration was lower with twice‐daily glargine (sd 3.2 ± 0.2 vs. 4.0 ± 0.3 mmol/l, P = 0.044). Plasma free insulin concentration was higher in the afternoon with twice‐daily glargine (21.9 ± 1.4 vs. 16.1 ± 1.3 mU/l, P = 0.009), but lower overnight (12.1 ± 1.7 vs. 17.8 ± 1.7 mU/l, P = 0.030), compared with once‐daily injection. Plasma glucose concentration overnight was higher with twice‐daily compared with once‐daily glargine (mean 9.0 ± 0.4 vs. 6.6 ± 0.4 mmol/l, P = 0.001).Conclusions Blood glucose concentration rises in the late afternoon in association with falling plasma insulin levels towards the end of the 24‐h period after insulin glargine injection in some people with Type 1 diabetes using once‐daily glargine at dinner‐time plus a rapid‐acting insulin analogue at meal‐times. This is prevented by twice‐daily injection of insulin glargine.Keywords
This publication has 18 references indexed in Scilit:
- Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross‐over trial in people with Type 1 diabetesDiabetic Medicine, 2006
- Optimal timing of injection of once‐daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal‐timesDiabetic Medicine, 2005
- Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes.Diabetes Care, 2000
- Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDMDiabetologia, 1994
- Sleep-associated fall in glucose disposal and hepatic glucose output in normal humans. Putative signaling mechanism linking peripheral and hepatic eventsDiabetes, 1989
- Demonstration of a Dawn Phenomenon in Normal Human VolunteersDiabetes, 1984
- Variation in125i-insulin absorption and blood glucose concentrationDiabetologia, 1979
- Day-to-day variation of continuously monitored glycaemia: A further measure of diabetic instabilityDiabetologia, 1972
- An exact test for comparing matched proportions in crossover designsBiometrika, 1969
- An Exact Test for Comparing Matched Proportions in Crossover DesignsBiometrika, 1969